An Open-Label, Multicenter, Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment
Latest Information Update: 29 Nov 2023
At a glance
- Drugs Lurbinectedin (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors PharmaMar
Most Recent Events
- 10 Nov 2021 New trial record